Relmada Therapeutics to present NDV-01 Phase 2 data at SUO meeting

Relmada Therapeutics (RLMD) announced that the previously disclosed 6-month follow-up data from the ongoing Phase 2 study of NDV-01, a sustained release, intravesical formulation of gemcitabine and docetaxel, in development for non-muscle invasive bladder cancer will be presented in a poster at the Society of Urologic Oncology 26th Annual Meeting. The poster will be presented by Yair Lotan, MD, Chairman of Relmada’s Clinical Advisory Board, on Thursday, December 4th at 2:30 PM MT in Phoenix, AZ. Raj Pruthi, MD, Chief Medical Officer-Oncology of Relmada Therapeutics, noted, “We believe NDV-01 has the opportunity to transform the treatment of NMIBC by providing patients and physicians with a potential bladder-sparing, in-office, ready-to-use, safe, effective and durable, best-in-class therapy. We are on track to initiate the Phase 3 program in H1 2026, building on the encouraging, recently announced 9-month data, showing a 92% complete response rate at any time point, and encouraging recent FDA discussions, which provide us with a well-defined registrational strategy in two distinct indications in NMIBC with limited treatment options.”